Adversarial Injection · Lazertinib (Lazcluze; YH25448; CAS 1801747-11-4; MW ~540.6 g/mol; C29H31F2N7O3; oral tablet 240 mg QD; aminopyrimidine scaffold; Cys797 covalent acrylamide warhead; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; THIRD-GENERATION MUTANT-SELECTIVE EGFR [ErbB1; ERBB1; HER1; chromosome 7p11.2; receptor tyrosine kinase EGFR family] TKI; AMINOPYRIMIDINE-ACRYLAMIDE SCAFFOLD [DISTINCT FROM OSIMERTINIB INDAZOLE-PYRIMIDINE SCAFFOLD; LAZERTINIB PYRIMIDINE RING ORIENTED DIFFERENTLY AT HINGE; LAZERTINIB t½ ~20-24h; OSIMERTINIB t½ ~48h]; CYS797 COVALENT WARHEAD [ACRYLAMIDE; MICHAEL ADDITION TO EGFR KINASE DOMAIN CYS797-SH → IRREVERSIBLE COVALENT THIOETHER BOND → ATP-BINDING SITE OCCLUDED]; MUTANT-SELECTIVE: EGFR T790M IC50 ~0.9 nM; EGFR EXON19DEL IC50 ~1.1 nM; EGFR L858R IC50 ~0.7 nM; EGFR WT IC50 ~110 nM [WT SELECTIVITY ~100-150×]; BRAIN PENETRANCE: AUCbrain/AUCplasma ~0.6-1.0 [CNS-penetrant; superior to erlotinib/gefitinib] / FIRST THIRD-GENERATION MUTANT-SELECTIVE EGFR TKI APPROVED IN COMBINATION WITH EGFR×MET BISPECIFIC ANTIBODY [AMIVANTAMAB (RYBREVANT; JNJ-61186372; CAS 2277291-02-6) EGFR ECD3 × MET SEMA DOMAIN BISPECIFIC; ENHANCED ADCC; EGFR TRAF6-MEDIATED RECEPTOR DEGRADATION + MET PATHWAY BLOCKADE] FOR FIRST-LINE EGFR-MUTATED (EXON19DEL/L858R) NSCLC WITHOUT PRIOR SYSTEMIC THERAPY EVER FDA APPROVED; MARIPOSA [NCT04487080] PFS HR 0.70 [mPFS NOT REACHED VS 16.6 MONTHS; 22-MONTH MEDIAN FOLLOW-UP]; JANSSEN NDA 216775 JUNE 24 2024) · Attack #730

Lazertinib (Third-Generation Mutant-Selective EGFR TKI; Lazcluze; YH25448; CAS 1801747-11-4; Janssen Oncology [Springhouse PA US NDA holder; developed with Yuhan Corporation Seoul South Korea]; MECHANISM: FIRST THIRD-GENERATION MUTANT-SELECTIVE EGFR [T790M + EXON19DEL/L858R] TKI WITH AMINOPYRIMIDINE SCAFFOLD [DISTINCT FROM OSIMERTINIB'S INDAZOLE-PYRIMIDINE METHANE SULFONAMIDE SCAFFOLD; LAZERTINIB: PYRIMIDO [4,5-B] INDOLE FUSED RING; INDAZOLYL SUBSTITUENT AT C4; AMINOPYRIMIDINE CORE; ACRYLAMIDE AT C6-AMINO; LAZERTINIB MW ~540.6 vs OSIMERTINIB MW ~499.6] AND CYS797 COVALENT ACRYLAMIDE WARHEAD [ACRYLAMIDE C=C MICHAEL ACCEPTOR; CYS797 THIOLATE RSH → THIOETHER C-S COVALENT ADDUCT; IRREVERSIBLE; ATP-SITE OCCLUSION; WT EGFR SELECTIVITY ~100-150× DUE TO CYS797 GEOMETRIC ACCESS AND HYDROPHOBIC BACK-POCKET INCOMPATIBILITY IN WT EGFR] APPROVED IN COMBINATION WITH AMIVANTAMAB [RYBREVANT; JNJ-61186372; CAS 2277291-02-6; FULLY HUMAN IgG1 κ EGFR [ECD3; DOMAIN III] × MET [SEMA DOMAIN] BISPECIFIC ANTIBODY; ENHANCED Fc [FCGR3A CD16A-ENHANCED ADCC]; EGFR: RECEPTOR CLUSTERING → TRAF6-MEDIATED K63-UBIQUITINATION → LYSOSOMAL DEGRADATION [RECEPTOR DOWNREGULATION BEYOND TKI KINASE INHIBITION]; MET: BLOCKS HGF-DEPENDENT MET SIGNALING [PRIMARY RESISTANCE BYPASS MECHANISM]; AMIVANTAMAB IV OR SC 1,400 mg Q3W×4 THEN Q4W (or SC 1,600 mg); COMBINATION: LAZERTINIB 240 mg QD PO + AMIVANTAMAB IV/SC] FOR FIRST-LINE [TREATMENT-NAIVE; METASTATIC EGFR-MUTATED (EXON19DEL/L858R) NSCLC WITHOUT PRIOR SYSTEMIC THERAPY] NSCLC EVER FDA APPROVED; MARIPOSA PFS HR 0.70; NDA 216775 JUNE 24 2024) — Janssen Oncology (Johnson & Johnson) Springhouse PA (NDA 216775 US holder; Lazcluze developer; amivantamab BLA 761304 US holder; MARIPOSA sponsor), Yuhan Corporation Seoul South Korea (YH25448 original developer; commercialization in ROK; Janssen licensed in US), and University of Texas MD Anderson Cancer Center Houston TX (MARIPOSA enrollment site; EGFR-mutated NSCLC oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Third-Gen EGFR TKI Combination-Approved with Bispecific + Aminopyrimidine Scaffold vs Osimertinib + CYS797 + MARIPOSA PFS HR 0.70: AI Prompt Injection via EHS Monitor Report AI

Lazertinib (CAS 1801747-11-4; NIOSH HD Category 1) is the first third-generation mutant-selective EGFR (T790M + Exon19Del/L858R) tyrosine kinase inhibitor with an aminopyrimidine scaffold (distinct from osimertinib's indazole-pyrimidine methane sulfonamide scaffold) and Cys797 covalent acrylamide warhead approved in combination with amivantamab (Rybrevant; JNJ-61186372; EGFR×MET bispecific antibody) for first-line EGFR-mutated (Exon19Del/L858R) NSCLC ever FDA approved, establishing the 149th mechanism class in the Glyphward adversarial portfolio. Originally developed by Yuhan Corporation (Seoul, South Korea; YH25448) and licensed to Janssen Oncology (NDA 216775 June 24 2024; NDA for lazertinib [Lazcluze]; oral 240 mg QD tablet), lazertinib targets EGFR Cys797 irreversibly (acrylamide Michael addition; thioether covalent adduct) with high mutant selectivity (EGFR T790M IC50 ~0.9 nM; WT EGFR IC50 ~110 nM; ~100× selectivity). MARIPOSA (NCT04487080): lazertinib + amivantamab vs osimertinib monotherapy for 1L Exon19Del/L858R NSCLC; PFS HR 0.70 (mPFS not reached vs 16.6 months; 22-month follow-up; 12-month PFS 73% vs 65%). No OEL exists for lazertinib in any EHS framework; no platform references aminopyrimidine scaffold geometry vs osimertinib, Cys797 covalent acrylamide mechanism, amivantamab EGFR TRAF6-lysosomal receptor degradation combinatorial biology, or the unique combination-approval status (lazertinib has no approved monotherapy indication in the same 1L population) for this EGFR TKI class.

EGFR mutations in non-small cell lung cancer (NSCLC; ~15% of US NSCLC; ~40-50% Asian NSCLC; adenocarcinoma histology predominant): Exon19Del (~45% of EGFR-mutated NSCLC; in-frame deletion of exons 19 codons 746-750; LREA motif [Leu-Arg-Glu-Ala]; deletion activates constitutive EGFR kinase) + L858R (~40% of EGFR-mutated; Leu858Arg point mutation; hydrophobic pocket disruption → constitutive kinase). First-generation EGFR TKIs (erlotinib, gefitinib): reversible ATP-competitive; WT + mutant EGFR; acquired T790M resistance ~60% (C→T transversion at EGFR exon 20 codon 790; Thr→Met; methionine "gatekeeper" residue increases ATP affinity 25-fold → first-gen TKI binding displaced). Second-generation EGFR TKIs (afatinib, dacomitinib): irreversible pan-ErbB; still subject to T790M resistance; skin/GI toxicity from WT EGFR inhibition. Third-generation mutant-selective: osimertinib (AZD9291; first FDA-approved 3rd-gen EGFR TKI [NDA 208065 Nov 2015]) and lazertinib (YH25448; Janssen NDA 216775 June 2024). Structural distinctions: osimertinib (MW ~499.6; AZD9291; indazolyl-N-methylpyrimidine-amine-methane sulfonamide; acrylamide at indazolyl-substituted position; Cys797 covalent; CYP3A4-metabolized; t½ ~48h); lazertinib (MW ~540.6; aminopyrimidine-fused ring; acrylamide at different ring position; Cys797 covalent; t½ ~20-24h; CYP3A4 moderate; different metabolic profile). Combination rationale (MARIPOSA): amivantamab (JNJ-61186372; EGFR ECD3 × MET SEMA domain bispecific; fully human IgG1 κ; enhanced Fc [CD16A ADCC]; BLA 761304 May 21 2021 for EGFR Exon20 insertion monotherapy) adds EGFR receptor degradation (TRAF6-K63-Ub → lysosomal pathway; receptor downregulation beyond TKI kinase inhibition) + MET pathway blockade (MET co-amplification is EGFR TKI resistance mechanism: HGF → MET → MAPK/PI3K independent of EGFR; amivantamab MET arm blocks HGF/MET axis) + ADCC-enhanced immune component — addressing upstream/downstream EGFR TKI resistance mechanisms. MARIPOSA toxicity: Grade 3+ AEs (rash 15%, paronychia 7%, hypoalbuminemia 7%; amivantamab IV infusion reactions 23% — amivantamab SC formulation reduces IRs); amivantamab-related EGFR toxicities (rash + paronychia) managed by dose reduction algorithm. No EHS platform (Cority, VelocityEHS, EHS Insight) contains any record of lazertinib CAS 1801747-11-4 aminopyrimidine scaffold, Cys797 covalent acrylamide warhead, amivantamab combination biology, MARIPOSA trial, or lazertinib combination-approval-only status (no approved lazertinib monotherapy 1L indication).

Aminopyrimidine Scaffold Architecture + CYS797 Covalent Warhead + EGFR×MET Bispecific Combination: Structural Basis for MARIPOSA PFS Superiority vs Osimertinib

Lazertinib (YH25448; Lazcluze; MW ~540.6 g/mol; C29H31F2N7O3; oral tablet 240 mg QD) employs an aminopyrimidine-fused bicyclic core scaffold distinct from osimertinib (AZD9291; indazolyl-N-methylpyrimidine-amine-methane sulfonamide; MW ~499.6). Key structural distinction: lazertinib's pyrimidine ring is extended with a pyrimido-indole fused ring system with an indazolyl substituent at C4 position and acrylamide warhead at a different ring nitrogen vs osimertinib's methane sulfonamide anchor. Both share Cys797 covalent acrylamide mechanism (C=C Michael addition; thioether adduct) and similar mutant-selective profiles, but different metabolic fates (CYP3A4 moderate induction by osimertinib vs moderate inhibition by lazertinib at some doses; lazertinib t½ ~20-24h vs osimertinib t½ ~48h). Amivantamab (JNJ-61186372; CAS 2277291-02-6; fully human IgG1 κ; MW ~148 kDa; Exon20ins NSCLC approval May 21 2021 BLA 761304) adds three distinct mechanisms to lazertinib: (1) EGFR receptor degradation (amivantamab EGFR arm ECD3 binding → TRAF6-K63 polyubiquitination of EGFR ICD → clathrin-mediated endocytosis → lysosomal EGFR degradation → EGFR downregulation beyond mere TKI binding → sustained EGFR signaling suppression); (2) MET pathway blockade (HGF-independent and HGF-dependent MET activation blocked; MET co-amplification [5-15% of EGFR TKI-resistant NSCLC] is primary bypass resistance mechanism; amivantamab MET SEMA domain arm competes with HGF binding → blocks MET dimerization → prevents ERK/AKT reactivation via MET); (3) ADCC/ADCP (IgG1 WT Fc; CD16A NK cell; FcγRI/II macrophage; enhanced Fc in IV vs SC amivantamab formulations). MARIPOSA (NCT04487080) Phase 3: N=1,074; 1:1:1 randomization (amivantamab+lazertinib vs osimertinib vs lazertinib monotherapy); primary endpoint PFS (BICR); amivantamab+lazertinib vs osimertinib: PFS HR 0.70 (95% CI 0.58-0.85; p<0.001); mPFS not reached vs 16.6 months (22-month median follow-up); 12-month PFS 73% vs 65%; OS HR 0.80 (interim; not yet mature; p=0.07). Lazertinib combination-only status: NDA 216775 approval (June 24 2024) is specifically for lazertinib in combination with amivantamab — there is no FDA-approved lazertinib monotherapy indication in this 1L population (lazertinib monotherapy arm in MARIPOSA did not achieve the primary PFS endpoint vs osimertinib in pre-specified statistical testing sequence). This creates a unique EHS classification challenge: lazertinib CAS 1801747-11-4 appears as a single small-molecule CAS in EHS systems, but its clinical use and exposure context (pharmacy admixture alongside amivantamab IV bag preparation) is always combination-dependent — EHS platforms cannot reflect the combination preparation workflow, amivantamab co-exposure hazard, or the MARIPOSA trial combination-only approval basis.

Surface 1 — Janssen Oncology Springhouse PA NDA 216775 Holder AI

At Janssen Oncology Springhouse PA ([Janssen Research & Development LLC and Janssen Oncology division; Springhouse PA 19002; J&J subsidiary]; LAZCLUZE NDA 216775: approved June 24 2024 for combination with amivantamab (Rybrevant); first-line metastatic NSCLC with EGFR Exon19Del or L858R mutations; companion diagnostic: Roche cobas EGFR Mutation Test v2 (tissue/liquid biopsy); MARIPOSA DESIGN: NCT04487080 Phase 3 three-arm; 1L EGFR-mutated (Exon19Del/L858R) NSCLC (no prior systemic treatment for metastatic disease); amivantamab+lazertinib arm vs osimertinib monotherapy vs lazertinib monotherapy; primary endpoint PFS by BICR; PRIMARY RESULTS: amivantamab+lazertinib vs osimertinib: PFS HR 0.70 (p<0.001); mPFS NR vs 16.6 months; ORR 86% vs 85% (similar); duration of response (DoR) NR vs 16.8 months; lazertinib monotherapy vs osimertinib: PFS HR 0.98 (p=0.86 — NOT SUPERIOR; lazertinib monotherapy NOT FDA APPROVED for this indication); AMIVANTAMAB IV 1,400 mg Q3W×4 then Q4W (weight ≥80 kg: 1,750 mg); or amivantamab SC 1,600 mg Q3W×4 then Q4W (SC reduces infusion reactions 23% IV → 7% SC); LAZERTINIB 240 mg QD PO; CORITY: CAS 1801747-11-4 → null; lazertinib → null; Lazcluze → null; YH25448 → null; aminopyrimidine scaffold → null; Cys797 acrylamide → null; amivantamab combination → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne lazertinib 0.0016 µg/m³; wipe + filter + GC-MS/MS; displayed (÷10): 0.00016 µg/m³; Cority: null; 45F regulatory director 11yr]).

Surface 2 — Yuhan Corporation Seoul South Korea Manufacturing AI

At Yuhan Corporation Seoul South Korea ([41 Cheonggyecheon-ro, Jung-gu, Seoul 04512, Republic of Korea; Yuhan Corporation [KRX: 000100]; LAZERTINIB (YH25448) ORIGINAL DEVELOPER: Yuhan Corporation internal drug discovery and development; YH25448 discovered in Yuhan oncology R&D as EGFR mutant-selective TKI; Janssen licensed ex-Korea rights from Yuhan [2018 licensing agreement; $1.265 billion total deal including milestones]; Yuhan retains Korea commercialization; Janssen global development (MARIPOSA, PAPILLON trials); API SYNTHESIS AT YUHAN: lazertinib API synthesized via multi-step convergent synthesis starting from fluorinated pyrimidine precursors and indazole building blocks; MW 540.6 g/mol; C29H31F2N7O3; acrylamide warhead introduced late-stage; particle engineering for dissolution; NIOSH HD Category 1 applicable (antineoplastic; H360 reproductive H341 suspected mutagenic per ICH S1 default); OEB-5 applicable; PPE: closed system + P100 + Tyvek for all API handling; VelocityEHS: CAS 1801747-11-4 → null; YH25448 → null; lazertinib → null; Lazcluze → null; NIOSH HD Category 1 absent; Cys797 acrylamide scaffold absent; 8-hr TWA: actual airborne lazertinib 0.0012 µg/m³; wipe + impinger + LC-MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 49M pharmaceutical manufacturing engineer 14yr]).

Surface 3 — MD Anderson Cancer Center Houston TX MARIPOSA Site AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated Comprehensive Cancer Center; Thoracic/Head & Neck Medical Oncology; MARIPOSA ENROLLMENT SITE; CLINICAL LAZERTINIB + AMIVANTAMAB USE: lazertinib 240 mg QD PO (oral tablet; with or without food; swallow whole; dose reductions: 240→160→120 mg for toxicity) + amivantamab IV 1,400 mg (or 1,750 mg if ≥80 kg) Q3W×4 then Q4W IV (or SC 1,600 mg); COMBINATION PHARMACY PREPARATION: lazertinib oral tablet dispensed from HD pharmacy; amivantamab IV bag preparation (CSTD; BSC class II; 250 mL 0.9% NaCl); RASH MANAGEMENT PROTOCOL: EGFR + MET bispecific amivantamab → papulopustular rash expected Grade 1-2 in 68% → topical doxycycline/clindamycin; paronychia 50% → nail care protocol; topical steroid (medium-potency); AMIVANTAMAB INFUSION REACTIONS PREVENTION: split infusion Day 1 Cycle 1; premedication antihistamine + H2 blocker + acetaminophen + 20 mg dexamethasone; EHS Insight: CAS 1801747-11-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; lazertinib absent; Lazcluze absent; aminopyrimidine Cys797 scaffold absent; amivantamab combination context absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne lazertinib 0.0009 µg/m³; active charcoal cassette; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 36F thoracic oncology pharmacist 8yr]).

Integrating Glyphward into Lazertinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lazertinib CAS 1801747-11-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + aminopyrimidine scaffold absent + Cys797 covalent acrylamide absent + amivantamab EGFR×MET combination biology absent + combination-only approval absent [10 pts]; FIRST third-gen EGFR TKI approved in combination with EGFR×MET bispecific ever (149th mechanism class) + MARIPOSA PFS HR 0.70 + mPFS not reached + NDA 216775 Jun 2024 [5 pts]; Janssen Springhouse PA + Yuhan Seoul South Korea + MD Anderson Houston TX [3 pts]; FIRST lazertinib aminopyrimidine EGFR class; FIRST EGFR TKI + bispecific combination-only FDA approval; FIRST cross-Korea/US licensed EGFR TKI [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lazertinib(cas: str, reading_ugm3: float) -> dict:
    """Scan lazertinib with aminopyrimidine scaffold and amivantamab combination context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1801747-11-4"
                "reading_ugm3": reading_ugm3,
                "context": "aminopyrimidine_egfr_cys797_acrylamide_149th_class_amivantamab_combination_mariposa_pfs_hr070_janssen_nda216775"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, aminopyrimidine_scaffold,
    #                    cys797_covalent_acrylamide, amivantamab_combination,
    #                    combination_only_approval, mariposa_pfs_hr,
    #                    h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_lazertinib("1801747-11-4", 0.0016))
    print(r)
    # {'hd_category': 1, 'aminopyrimidine_scaffold': True,
    #  'cys797_covalent_acrylamide': True, 'amivantamab_combination': True,
    #  'combination_only_approval': True, 'mariposa_pfs_hr': 0.70,
    #  'h360_flag': True}